Ontology highlight
ABSTRACT:
SUBMITTER: Gozgit JM
PROVIDER: S-EPMC3236248 | biostudies-literature | 2011 Jun
REPOSITORIES: biostudies-literature
Gozgit Joseph M JM Wong Matthew J MJ Wardwell Scott S Tyner Jeffrey W JW Loriaux Marc M MM Mohemmad Qurish K QK Narasimhan Narayana I NI Shakespeare William C WC Wang Frank F Druker Brian J BJ Clackson Tim T Rivera Victor M VM
Molecular cancer therapeutics 20110411 6
Ponatinib (AP24534) is a novel multitargeted kinase inhibitor that potently inhibits native and mutant BCR-ABL at clinically achievable drug levels. Ponatinib also has in vitro inhibitory activity against a discrete set of kinases implicated in the pathogenesis of other hematologic malignancies, including FLT3, KIT, fibroblast growth factor receptor 1 (FGFR1), and platelet derived growth factor receptor α (PDGFRα). Here, using leukemic cell lines containing activated forms of each of these recep ...[more]